Haleos Labs Limited vs Sandu Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 09, 2026

Key Highlights

The Latest Trading Price of Haleos Labs Limited is ₹ 1616 as of 08 May 15:30 . The P/E Ratio of Haleos Labs Limited changed from 13.7 on March 2023 to 8.3 on March 2022 . This represents a CAGR of -9.54% over 5 yearsThe P/E Ratio of Sandu Pharmaceuticals Ltd changed from 33.3 on March 2023 to 0 on March 2022 . This represents a CAGR of -100.00% over 5 years The Market Cap of Haleos Labs Limited changed from ₹ 157.21 crore on March 2023 to ₹ 210.12 crore on March 2022 . This represents a CAGR of 5.97% over 5 yearsThe Market Cap of Sandu Pharmaceuticals Ltd changed from ₹ 50.43 crore on March 2023 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 5 years The revenue of Haleos Labs Limited for the Dec '25 is ₹ 94.97 crore as compare to the Sep '25 revenue of ₹ 81.79 crore. This represent the growth of 16.11% The revenue of Sandu Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Haleos Labs Limited for the Dec '25 is ₹ 14.23 crore as compare to the Sep '25 ebitda of ₹ 13.99 crore. This represent the growth of 1.72% The ebitda of Sandu Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Haleos Labs Limited changed from ₹ 7.1 crore to ₹ 6.65 crore over 7 quarters. This represents a CAGR of -3.67% The net profit of Sandu Pharmaceuticals Ltd changed from ₹ 0.17 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The Dividend Payout of Haleos Labs Limited changed from 3.44 % on March 2021 to 2.12 % on March 2025 . This represents a CAGR of -9.23% over 5 yearsThe Dividend Payout of Sandu Pharmaceuticals Ltd changed from 36.33 % on March 2021 to 49.86 % on March 2025 . This represents a CAGR of 6.54% over 5 years .

About Haleos Labs Limited

SMS Lifesciences India Limited was incorporated originally as 'Potluri Real Estate Private Limited' on May 31, 2006.
The Company's name was changed to 'Potluri Packaging Industries Private Limited' on 6 November, 2013 and again changed to 'SMS Lifesciences India Private Limited on 4 August, 2014 to undertake the activities related pharma sector.
The Company became a wholly owned subsidiary Company of SMS Pharmaceuticals Limited w.e.f. 01.04.2016 and subsequently got converted into a Public Limited w.e.f. 22 June, 2016. The Company is engaged in the business of manufacturing and export of Active Pharma Ingredients(APIs) and their intermediates.
The Company is having manufacturing facilities at Kazipally and Jeedimetla, Hyderabad with an installed capacity of 65 KL. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having products spread across an array of therapeutic segments.

About Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Limited (SPL) was established in 1987.
The Company is mainly engaged in the business of manufacturing and trading of Ayurvedic medicines under the brand name 'SANDU' and is having a plant unit in Goa. SPL came out with a public issue of 17.70 lac equity shares at par, aggregating Rs 1.77 cr, in Sep.'94, to part-finance its new project in Goa costing Rs 7.28 cr to manufacture ayurvedic medicines and formulations.
This plant employs the latest material handling systems and other modern machinery and has the most hygienic production facilities to attain the highest possible quality standards.
Ayurvedic products have a very good market in India and abroad due to their minimal side effects. The company commenced commercial production of Ayurvedic Medicines & Formulations, at the Goa plant in 1996-97.

FAQs for the comparison of Haleos Labs Limited and Sandu Pharmaceuticals Ltd

Which company has a larger market capitalization, Haleos Labs Limited or Sandu Pharmaceuticals Ltd?

Market cap of Haleos Labs Limited is 488 Cr while Market cap of Sandu Pharmaceuticals Ltd is 37 Cr

What are the key factors driving the stock performance of Haleos Labs Limited and Sandu Pharmaceuticals Ltd?

The stock performance of Haleos Labs Limited and Sandu Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Haleos Labs Limited and Sandu Pharmaceuticals Ltd?

As of May 9, 2026, the Haleos Labs Limited stock price is INR ₹1616.7. On the other hand, Sandu Pharmaceuticals Ltd stock price is INR ₹39.32.

How do dividend payouts of Haleos Labs Limited and Sandu Pharmaceuticals Ltd compare?

To compare the dividend payouts of Haleos Labs Limited and Sandu Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.